Zepbound
The brand name for tirzepatide injection approved by the FDA in 2023 for chronic weight management. Same active ingredient as Mounjaro but indicated for obesity rather than diabetes.
What does Zepbound mean in peptide research?
The brand name for tirzepatide injection approved by the FDA in 2023 for chronic weight management. Same active ingredient as Mounjaro but indicated for obesity rather than diabetes. This term is part of the broader field of peptide research, which encompasses both FDA-approved therapeutic peptides and research-grade compounds used in scientific investigation.
Why this term matters
Understanding Zepbound is foundational for anyone reviewing peptide research literature, comparing different research compounds, or following regulatory developments in this field. The term appears across pharmacology textbooks, FDA documentation, and clinical trial reports.
Where to learn more
For deeper context, see our peptide research articles: